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Pro-opiomelanocortin and its 
Processing Enzymes Associate 
with Plaque Stability in Human 
Atherosclerosis – Tampere Vascular 
Study
Petteri Rinne  1,2, Leo-Pekka Lyytikäinen  3, Emma Raitoharju3, James J. Kadiri1, 
Ivana Kholova4, Mika Kähönen5, Terho Lehtimäki3 & Niku Oksala3,6
α-melanocyte-stimulating hormone (α-MSH) is processed from pro-opiomelanocortin (POMC) 
and mediates anti-inflammatory actions in leukocytes. α-MSH also promotes macrophage reverse 
cholesterol transport by inducing ATP-binding cassette transporters ABCA1 and ABCG1. Here we 
investigated the regulation of POMC and α-MSH expression in atherosclerosis. First, transcript 
levels of POMC and its processing enzymes were analyzed in human arterial plaques (n = 68) and 
non-atherosclerotic controls (n = 24) as well as in whole blood samples from coronary artery disease 
patients (n = 55) and controls (n = 45) by microarray. POMC expression was increased in femoral plaques 
compared to control samples as well as in unstable advanced plaques. α-MSH-producing enzyme, 
carboxypeptidase E, was down-regulated, whereas prolylcarboxypeptidase, an enzyme inactivating 
α-MSH, was up-regulated in unstable plaques compared to stable plaques, suggesting a possible 
reduction in intraplaque α-MSH levels. Second, immunohistochemical analyses revealed the presence 
of α-MSH in atherosclerotic plaques and its localization in macrophages and other cell types. Lastly, 
supporting the role of α-MSH in reverse cholesterol transport, POMC expression correlated with 
ABCA1 and ABCG1 in human plaque and whole blood samples. In conclusion, α-MSH is expressed in 
atherosclerotic plaques and its processing enzymes associate with plaque stability, suggesting that 
measures to enhance the local bioavailability of α-MSH might protect against atherosclerosis.
Atherosclerosis is a chronic inflammatory disease that is driven by persistent lipid overload, immune activation 
and accumulation of monocyte-derived macrophages in the growing lesions1,2. The disease progression is largely 
a matter of unresolved inflammation that is characterized by continuous recruitment of pro-inflammatory leu-
kocytes, macrophage proliferation and defective efferocytosis to clear apoptotic cells. These events gradually lead 
to expansion of necrotic core and thinning of fibrous cap overlying the core, which are hallmarks of a vulnerable 
plaque at high risk to rupture and cause acute complications. Therefore, investigating the molecular and cellular 
processes that contribute to the disease progression is fundamental and aids to identify novel therapeutic targets 
that could boost inflammation resolution and provide plaque-stabilizing effects.
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Pro-opiomelanocortin (POMC) is a multipotent prohormone that gives rise to smaller peptide hormones 
through post-translational processing3. These peptides include adrenocorticotropic hormone (ACTH) and α-, 
β- and γ-melanocyte-stimulating hormones (MSH) that are collectively called melanocortins. POMC is predom-
inantly expressed in the pituitary gland, particularly in the corticotrophs and melanotrophs of the anterior and 
intermediate lobes. It is also found in distinct nuclei in the central nervous system, in a variety of peripheral tis-
sues (e.g. skin, kidney, and liver) and in the cells of the immune system including monocytes and macrophages4. 
According to the current understanding, POMC-derived peptides are released into circulation by the pituitary 
gland, whereas in other tissues, POMC is processed to act in an autocrine or paracrine manner. The formation of 
biologically active melanocortins requires well-coordinated actions by several enzymes3. The expression of these 
enzymes is spatially and temporally regulated and co-localizes in POMC-expressing cells. The post-translational 
processing is initiated by prohormone convertases, PC1/3 and PC2, the former generating larger fragments from 
the POMC and the latter continuing the cleavage into smaller peptides such as ACTH1–17. Further processing of 
ACTH1–17 to yield mature α-MSH (Ac-ACTH1–13-NH2) is driven by carboxypeptidase E (CPE) and α-amidating 
monooxygenase (PAM). α-MSH has a very short half-life since it is rapidly metabolized by an enzyme, prolylcar-
boxypeptidase (PRCP), which inactivates α-MSH by removing the C-terminal valine residue5.
POMC-derived melanocortins bind and activate a family of G-protein coupled melanocortin receptors 
(MC1R-MC5R) to exert their physiological functions. Since the early discoveries of the pigmentary function of 
α-MSH and the role of ACTH in glucocorticoid production, our understanding of the melanocortins and their 
receptors has greatly advanced and we now appreciate that they contribute to diverse physiological functions 
ranging from appetite control to blood pressure regulation and immunomodulation6. For example, the role of 
α-MSH extends well beyond skin pigmentation. Through the interaction with its natural receptor MC1R, α-MSH 
not only elicits potent and well-established anti-inflammatory responses in leukocytes but also regulates endothe-
lial NO production and vascular tone7–9. We also recently identified that α-MSH promotes macrophage choles-
terol efflux and thereby protects against foam cell formation by activating MC1R10. Mechanistically, α-MSH was 
shown to induce the expression of ATP-binding cassette transporters ABCA1 and ABCG1, which mediate mac-
rophage cholesterol efflux onto high-density lipoprotein (HDL) particles11. This is an important mechanism that 
helps to resolve cholesterol accumulation and inflammation in atherosclerotic plaques, thus promoting plaque 
regression, and could ideally complement other lipid-lowering therapies in the management of atherosclerotic 
cardiovascular disease12,13.
Owing to its role in the control of inflammation, vascular tone and inflammation, α-MSH possesses numerous 
properties that could favorably modulate the progression of atherosclerosis and stabilize existing plaques. This 
prompted us to investigate whether POMC, α-MSH and the related processing enzymes are expressed locally in 
human atherosclerotic plaques. Based on our previous findings showing that genetic overexpression of α-MSH 
and pharmacological administration of its stable analogue protect against atherosclerosis14,15, we hypothesized 
that the expression of POMC-derived α-MSH associate with plaque stability and may become disturbed during 
progression to unstable advanced lesions.
Results
POMC expression is up-regulated in unstable atherosclerotic plaques. We first aimed to test the 
hypothesis that POMC and its processing product α-MSH are expressed in human atherosclerotic plaques. In a 
microarray-based analysis, which has been previously validated and shown good accuracy in comparison with 
real-time quantitative PCR16, POMC was expressed in all plaque samples including carotid artery, abdominal 
aortic and femoral artery plaques. The expression level of POMC in carotid or abdominal samples was not sig-
nificantly different in comparison with atherosclerosis-free left internal thoracic artery (LITA) samples (Fig. 1A). 
However, femoral arterial plaques showed subtle but significant up-regulation (fold change, FC = 1.2, P = 0.04) 
of POMC compared to control samples (Fig. 1A). Interestingly, when comparing stable and unstable advanced 
lesions, POMC transcript levels were increased in unstable plaque samples (Fig. 1B).
Gene association analyses revealed that POMC expression correlated positively with general macrophage 
markers such as CD68 and CSF1R in carotid and abdominal plaque samples (Fig. 1C), while the associations were 
absent in femoral plaques and in LITA samples (Fig. 1C). POMC also positively correlated with established sig-
nature markers of pro-inflammatory M1 and anti-inflammatory M2 type macrophages17,18 particularly in carotid 
plaques (Fig. 2A–C), but the association patterns were not markedly different between M1 and M2 markers. In 
contrast, the associations between POMC and SMC markers was negative in carotid and abdominal plaque sam-
ples (Fig. 2D,E), while femoral plaques showed relatively weak correlation with SMC markers (Fig. 2F). In line 
with these results, similar analyses in stable and unstable samples revealed that the strength of correlation with 
M1/M2 macrophage and SMC plaque signatures was weaker in unstable advanced plaques (Fig. 3). Collectively, 
POMC was up-regulated in femoral plaques as well as in unstable plaques and these changes were associated with 
blunted correlation patterns with macrophage and SMC markers.
Human and mouse atherosclerotic plaques express α-MSH. To study whether plaque POMC 
expression leads to detectable traits of its main processing product α-MSH, carotid plaque sample was immu-
nostained with an antibody against α-MSH. Conventional immunohistochemistry confirmed the presence of 
α-MSH in in the atherosclerotic plaque, particularly in close proximity to the arterial lumen (Fig. 4A). Double 
immunofluorescence further revealed that α-MSH merged with Mac-2 staining in the lesion (Fig. 4B), indi-
cating co-localization in macrophages. Consistently, aortic root plaques from Apoe−/− mice showed distinct 
α-MSH expression on Mac-2-positive macrophages as well as on the intimal layer (Supplementary Fig. IA), sup-
porting our earlier finding of endothelial α-MSH expression in healthy arteries9. It was also found that plaque 
α-MSH expression reduced in advanced atherosclerosis when Apoe−/− mice fed an atherogenic high-fat diet 
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(Supplementary Fig. IB and C). In contrast to declining α-MSH amount, POMC expression was increased in the 
aorta of Apoe−/− mice after high-fat diet (Supplementary Fig. ID).
POMC expression correlates with reverse cholesterol transporters in atherosclerotic plaques 
and in whole blood samples. Further screening of carotid plaque samples uncovered that POMC expres-
sion is directly associated with the reverse cholesterol transporters ABCA1, ABCG1 and scavenger receptor class 
B member 1 (SCARB1) (Fig. 5), which is in good agreement with our previous study demonstrating similar asso-
ciations with MC1R expression10. Of note, the correlations with ABCA1 and ABCG1 expression were stronger 
(r = 0.64, P = 0.0002 for both in carotid samples) than with any of the other analyzed macrophage and SMC 
markers, suggesting that POMC is centrally involved in the regulation of reverse cholesterol transport. These 
correlation patterns were somewhat evident also in abdominal plaque samples (Fig. 5), while femoral plaques 
showed no clear correlation with ABCA1, ABCG1 or SCARB1 (Fig. 5).
To further investigate the association between POMC and reverse cholesterol transporters, we analyzed whole 
blood and circulating monocyte samples from patients with coronary artery disease (CAD) and compared them 
with angiographically normal controls (non-CAD). The expression of POMC, ABCA1, ABCG1 or SCARB1 
did not differ between CAD and non-CAD samples in either whole blood or monocyte samples (Fig. 6A–D 
and Supplementary Fig. IIA–D). However, POMC expression was found to negatively associate with ABCA1 
(P = 0.010), ABCG1 (P = 0.0004) and SCARB1 (P = 0.0088) in the whole blood samples of non-CAD controls, 
while these correlations were completely absent in patients with CAD (P > 0.2 for all, Fig. 6E). The correlations 
with ABCA1, ABCG1 and SCARB1 were stronger compared to classical pro-inflammatory or anti-inflammatory 
Figure 1. Expression of pro-opiomelanocortin (POMC) in human atherosclerotic plaques. (A) Pro-
opiomelanocortin (POMC) expression in atherosclerosis-free control arteries (left internal thoracic artery; 
LITA, n = 24) and in endarterectomy samples from the carotid artery (n = 29), abdominal aorta (n = 15) 
and femoral artery (n = 24). LITA samples served as controls and they were histologically verified to be 
atherosclerosis-free. *P < 0.05 for the indicated comparison (one-way ANOVA and Bonferroni post hoc test). 
(B) POMC expression in stable and unstable plaque phenotypes in a subgroup of advanced plaques (stage V 
and VI). Exact P-value (two-tailed Student’s t test) is given in the graph. (C) Correlation between POMC mRNA 
levels and general macrophage markers in control LITA samples and in carotid, abdominal and femoral plaque 
samples. Pearson correlation coefficient (r) values are presented in the column graphs. *P < 0.05, **P < 0.01 and 
***P < 0.001 for correlation significances.
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markers (Fig. 6F,G). In non-CAD samples, POMC expression correlated negatively with pro-inflammatory IL-1β 
(r = −0.34, P = 0.017) and positively with anti-inflammatory IL-10 (r = 0.33, P = 0.021). In contrast to the whole 
blood analysis, monocyte fractions from the same individuals did not show any association between POMC 
expression and reverse cholesterol transporters in either non-CAD or CAD study population (Supplementary 
Fig. IIE). Likewise, no significant associations were noted between POMC and pro- or anti-inflammatory 
cytokines (Supplementary Fig. IIF and G).
Enzymes involved in the processing of POMC are associated with atherosclerotic plaque stabil-
ity. To gain further insights into the regulation of POMC processing in atherosclerosis, plaque samples were 
investigated for the expression of major enzymes involved in the proteolytic cleavage of POMC into biologically 
active peptides. The analyzed genes were PCSK1 and PCSK2 that encode PC1/3 and PC2, respectively, and regu-
late the first steps of POMC cleavage as well as CPE and PAM, which are more critical in the formation of mature 
α-MSH. Plaque samples were also screened for PRCP gene that was recently identified to inactivate α-MSH by 
degradation5. Firstly, POMC expression was found to negatively associate with CPE in carotid and abdominal 
plaque samples (Supplementary Fig. IIIA and B), while the correlation between POMC and PRCP was positive 
in carotid samples (Supplementary Fig. IIIA). Femoral plaques showed no distinct correlation between POMC 
and its processing enzymes (Supplementary Fig. IIIC). Secondly, gene expression levels of CPE, PAM and PRCP 
were studied between control samples and different plaque types as these genes are centrally involved in the 
maturation and degradation of α-MSH. CPE expression was specifically down-regulated (FC = −1.3, P = 0.03) 
in carotid plaques compared to LITA controls (Fig. 7A). PAM expression was significantly reduced in abdominal 
(FC = −1.4, P = 0.0001) and femoral (FC = −1.3, P = 0.002) plaques (Fig. 7B). In contrast, PRCP was consistently 
Figure 2. POMC expression in human atherosclerotic plaques is positively correlated with M1 and M2 
macrophage markers and negatively with smooth muscle cell markers. (A–C) Correlation between POMC 
mRNA levels and established M1 (grey columns) and M2 (black columns) macrophage markers in carotid 
(A), abdominal (B) and femoral (C) plaque samples. (D–F) Correlation between POMC mRNA levels and 
smooth muscle cell markers in carotid (A), abdominal (B) and femoral (C) plaque samples. Pearson correlation 
coefficient (r) values are presented in the column graphs. *P < 0.05, **P < 0.01 and ***P < 0.001 for correlation 
significances.
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Figure 3. Association of POMC transcript with M1/M2 macrophage and smooth muscle cell markers is 
attenuated in unstable advanced plaques. (A,B) Correlation between POMC mRNA levels and established M1 
(grey columns) and M2 (black columns) macrophage markers in stable and unstable plaques. (C,D) Correlation 
between POMC mRNA levels and smooth muscle cell markers in stable and unstable advanced plaques. 
Pearson correlation coefficient (r) values are presented in the column graphs. *P < 0.05 and **P < 0.01 for 
correlation significances.
Figure 4. α-melanocyte stimulating hormone (α-MSH) is expressed by plaque macrophages in human 
atheroma. (A) α-MSH immunostaining (brown color) of carotid endarterectomy sample. Scale bars, 200 µm 
(left) and 50 µm (right). (B) A consecutive section of the carotid sample was immunofluorescently stained for 
α-MSH (red) and Mac-2 (green), and counterstained with DAPI. Cells that clearly express both α-MSH and 
Mac-2 are indicated by white arrows. Scale bars, 200 µm (left) and 50 µm (right).
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up-regulated (FC = 1.4–1.6) in all arterial beds (Fig. 7C). Further analysis of type V and VI advanced lesions 
revealed that CPE transcript levels were reduced (FC = −1.3, P = 0.04) and PRCP levels increased (FC = 1.3, 
P = 0.003) in unstable atherosclerotic plaques compared to stable samples (Fig. 7D,F), while PAM expression 
did not significantly differ between stable and unstable plaques (Fig. 7E). Gene association analyses showed that 
CPE expression correlated negatively with macrophage-specific signature, most notably with M2 macrophage 
markers, and positively with SMC-rich plaque signature (Supplementary Fig. IV). Likewise, PAM mRNA levels 
correlated negatively with M1/M2 macrophage markers and positively with SMC markers (Supplementary Fig. 
V), whereas completely opposite patterns were observed for PRCP (Supplementary Fig. VI). In general, these 
association patterns were strongest in carotid plaques (Supplementary Figs IV–VI). Lending support to the role 
of α-MSH in reverse cholesterol transport, CPE and PAM showed negative correlation with ABCA1, ABCG1 
and SCARB1 in all plaque types. (Supplementary Fig. VII). PRCP transcript levels correlated positively with the 
reverse cholesterol transporters particularly in carotid plaque samples (Supplementary Fig. VII). Lastly, PRCP, 
which showed most significant changes at the mRNA level, was further studied by immunohistochemistry in the 
Figure 5. POMC expression is directly associated with reverse cholesterol transporters in carotid artery 
plaques. (A–C) Correlations between POMC expression and ATP-binding cassette transporter A1 (ABCA1), 
G1 (ABCG1) and scavenger receptor class B member 1 (SCARB1) expression in carotid (left panel), abdominal 
(middle panel) and femoral (right panel) atherosclerotic plaques. Pearson correlation coefficients (r) and P 
values are presented in the graphs.
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Figure 6. POMC expression negatively correlates with reverse cholesterol transporters in the whole blood, but 
the association is abolished in coronary artery disease. (A–D) POMC, ABCA1, ABCG1 and SCARB1 mRNA 
levels in whole blood samples of patients with history of coronary artery disease (CAD) and of individuals 
without coronary lesions (non-CAD). Exact P values (two-tailed Student’s t test) are presented in the graphs. 
(E) Correlations between POMC expression and ABCA1, ABCG1 and SCARB1 expression in whole blood 
samples from non-CAD and CAD individuals. Pearson correlation coefficients (r) and P values are presented 
in the graphs. (F,G) Correlation between POMC mRNA levels and established M1 (grey columns) and M2 
(black columns) macrophage markers in non-CAD (n = 48) and CAD (n = 47) whole blood samples. Spearman 
correlation coefficient (r) values are presented in the column graphs. The dashed lines are placed at 0.39 and 
−0.39 that represent the correlation level between POMC and ABCA1/SCARB1. *P < 0.05 for correlation 
significances.
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human atherosclerotic plaque. PRCP protein was expressed in the atherosclerotic plaque and it mainly localized 
to Mac-2 positive macrophages (Fig. 8).
Discussion
The present study aimed at investigating the expression of POMC and POMC-related enzymes in human ather-
osclerosis. Here, we demonstrate that in POMC is not only expressed at the mRNA level but also processed into 
mature and biologically active cleavage product, namely α-MSH, in the atherosclerotic plaque. The expression of 
POMC-processing enzymes associated with plaque stability in a congruent manner, pointing towards a possible 
reduction of α-MSH in unstable advanced plaques. Lastly and consistent with our previous findings, POMC 
expression correlated positively with the reverse cholesterol transporters ABCA1, ABCG1 and SCARB1 in ath-
erosclerotic plaques. However, in whole blood samples, the correlations were negative with signs of regulatory 
disturbance occurring after the development of CAD.
Our results indicate that POMC expression correlates with macrophage-rich gene signature in atherosclerotic 
plaque, suggesting that macrophages are a possible source of the pro-hormone POMC and its cleavage products. 
This notion is further supported by the finding of co-localization of α-MSH with the macrophage marker Mac-2 
in immunofluorescence staining. Indeed, considering POMC production in different leukocyte subpopulations, 
the largest body of evidence demonstrates that macrophages are capable of producing α-MSH and that the rate 
of production is responsive to acute inflammatory stimuli19–21. The observations that femoral plaque samples 
showed higher POMC expression than atherosclerosis-free control arteries and that unstable plaques had sim-
ilarly increased POMC transcript levels in comparison with stable plaques indicate that atherosclerosis induces 
changes in the regulation of POMC expression. Up-regulation of POMC had also resulted in blunted correla-
tion patterns with macrophage and SMC markers in these samples, which points to a possible disturbance in 
POMC processing or to enhanced degradation of α-MSH. This notion is supported by the finding of discordant 
POMC and α-MSH expression levels in the aorta of Apoe−/− mice, i.e. increased POMC and falling α-MSH 
level in response to diet-induced atherosclerosis. The mouse data provides persuasive evidence that POMC is 
Figure 7. Prolylcarboxypeptidase, an enzyme degrading α-MSH, is upregulated in unstable atherosclerotic 
plaques. (A–C) The expression of CPE, PAM and PRCP expression in control arteries (LITA) and in carotid 
artery, abdominal and femoral atherosclerotic samples. CPE, carboxypeptidase E; PAM, peptidylglycine 
α-amidating monooxygenase; PRCP, prolylcarboxypeptidase *P < 0.05, **P < 0.01 and ***P < 0.001 for 
the indicated comparisons (one-way ANOVA and Bonferroni post hoc test). (D–F) CPE and PRCP mRNA 
expression in stable and unstable advanced atherosclerotic plaques. Exact P values (two-tailed Student’s t test) 
are given in the graphs.
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up-regulated as a compensatory response to disturbed POMC processing and/or accelerated inactivation of 
α-MSH. Further research will be fundamental to explore how atherosclerosis affects POMC processing in mice 
and humans. It is well-known that local formation of α-MSH necessitates sequential actions of several enzymes in 
the biosynthetic pathway. PC1/3 and PC2 operate upstream in the pathway, while processing of ACTH to mature 
α-MSH is driven by CPE, PAM and NAT3. In view of the fact that POMC gives rise to a versatile array of bioac-
tive peptides, it is clear that POMC gene has a complex promoter/enhancer structure and its expression is tightly 
regulated by numerous transcription factors22. Accordingly, the expression of CPE, PAM and NAT might more 
accurately reflect changes in the biosynthesis rate of α-MSH.
Another line of evidence from the present study strengthens the concept that α-MSH and its cognate recep-
tor MC1R contribute to the regulation of reverse cholesterol transport. We had previously observed that MC1R 
expression correlates with ABCA1, ABCG1 and SCARB1 in human and mouse atherosclerotic plaques and that 
α-MSH has also a functional effect on reverse cholesterol transport by activating MC1R in macrophages10. The 
present findings indicate a positive correlation between POMC and the cholesterol transporter genes in carotid 
plaques. ABCA1 and ABCG1 initiate the first step of reverse cholesterol transport and counter-balance the cho-
lesterol burden of macrophage-derived foam cells, thus providing protection against atherosclerosis and devel-
opment of vulnerable plaque phenotype11–13. SCARB1 is considered as the HDL receptor due to its central role in 
regulating cholesterol uptake from HDL particles in the liver23,24. It also mediates bidirectional lipid transport in 
macrophages and is associated with the development of atherosclerosis25,26. Against this background, the expres-
sion of POMC in lesional macrophages might provide an atheroprotective mechanism by regulating reverse cho-
lesterol transport in an autocrine or paracrine manner in the plaque environment.
Interestingly, the expression of POMC in whole blood samples correlated with reverse cholesterol transport-
ers and the presence of CAD seemed to abrogate this association. However, the direction of correlation was 
negative and thereby contradicts the findings in arterial plaque samples. One possible explanation for this dis-
crepancy might be that the regulation between POMC and reverse cholesterol transporters is completely differ-
ent in circulating leukocytes compared to lesional macrophages. Another finding from the association analyses 
with non-CAD and CAD samples was that the correlation appeared in whole blood samples and not in circu-
lating monocyte fractions. POMC transcripts have been found in a variety of immune cells, including mono-
cytes, neutrophils and lymphocytes27–29. Thus, it is conceivable that the interaction between POMC and ABCA1/
ABCG1 may occur primarily in neutrophils or in lymphocytes. However, little is known about the role and reg-
ulation of reverse cholesterol transporters in other leukocyte subsets than monocytes and their descendant mac-
rophages11,25. The lack of association between POMC and ABCA1/ABCG1 in monocytes could be on the other 
hand caused by sample processing for monocyte isolation and its influence on gene expression. Clearly, further 
studies are warranted to investigate how POMC and its processing products regulate ABCA1/ABCG1 expression 
in circulating leukocytes and what is the pathological significance of the observed lack of association in CAD.
In addition to subtle changes in POMC expression between different plaque types, further analyses uncovered 
that the enzymes responsible for the processing and maturation of α-MSH are down-regulated in atherosclerotic 
plaques, while α-MSH inactivating PRCP expression is increased in plaque samples. Similar changes associated 
also with unstable plaque phenotype, suggesting that POMC processing might be further disturbed during plaque 
progression to a vulnerable lesion at high risk for rupture. In terms of correlation with pro-inflammatory M1 
Figure 8. The expression and localization of PRCP in the human atherosclerotic plaque. (A) Immunohistochemical 
staining of PRCP (brown color) in a carotid endarterectomy sample. Scale bars, 500 µm (left) and 50 µm (right).  
(B) A consecutive section of the carotid sample was immunofluorescently stained for PRCP (red) and Mac-2 (green), 
and counterstained with DAPI. Cells that clearly express both PRCP and Mac-2 are indicated by white arrows. Scale 
bars, 500 µm (left) and 50 µm (right).
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type and anti-inflammatory M2 type macrophage markers, no clear-cut polarization towards either macrophage 
type was observed for the studied enzymes except for CPE, which mostly correlated with M2 type markers. Thus, 
CPE-driven α-MSH maturation could occur primarily in anti-inflammatory M2 type macrophages, which are 
typically enriched in regressing lesions and are likely to be atheroprotective30,31. Reduced CPE and PAM expres-
sion and increased PRCP expression are likely to reduce the local availability of α-MSH in the lesions. The finding 
of reduced α-MSH expression in advanced lesions of Apoe−/− mice lends support to the view that its amount 
might decline during the progression of human atherosclerosis. Given that pharmacological or genetic α-MSH 
overexpression promotes an anti-inflammatory plaque phenotype and limits atherosclerosis10,14,15, reduced 
α-MSH level could induce a reverse phenotype and thus be a contributing factor for the development of vulner-
able plaque. However, the expressional changes of CPE, PAM and PRCP are indirect markers and provide only 
suggestive evidence that α-MSH bioavailability might be affected. CPE and PAM not only process ACTH into 
biologically active α-MSH but they are also involved in the generation of other POMC-derived products includ-
ing β-MSH, γ-MSH and β-endorphins3. Secondly, PRCP was only recently identified to inactivate α-MSH5,32, 
while the earlier evidence demonstrate its central role in the metabolism of angiotensin II and III as well as in 
the activation of prekallikrein to kallikrein33,34. Even if other peptide systems are also modulated, the observed 
changes in PAM, CPE and PRCP transcript levels suggest a synergistic effect on lowering tissue α-MSH levels.
From a drug development perspective, PRCP represents an attractive therapeutic target to augment the bio-
availability of α-MSH for the treatment of cardiometabolic diseases35,36. For example, PRCP deficient mice exhibit 
reduced food intake and resistance to diet-induced obesity due to elevated α-MSH levels5. Similar effects have 
been also reproduced by using small-molecule inhibitors of PRCP5,37. Extending the experimental findings to 
a clinical perspective, plasma concentration of PRCP was found to associate with obesity, diabetes and signs of 
atherosclerotic plaque formation38. These findings are in agreement with the present study showing up-regulated 
PRCP expression particularly in unstable advanced plaques. However, owing to its role in processing vasoactive 
peptides, PRCP has been also implicated in the regulation of blood pressure, angiogenesis and endothelial inflam-
mation39–41, highlighting the complexity of the involved molecular pathways. Further research will be therefore 
fundamental to characterize the overall outcome and safety of PRCP inhibition.
As a potential limitation of the study, plaque samples were compared to atherosclerosis-free LITAs instead 
of corresponding normal arteries from carotid, aortic and femoral regions due to ethical issues. Because 
of the systemic nature of atherosclerosis, LITA samples and their gene expression profile may be affected by 
pro-inflammatory signaling and other humoral mechanisms that are driving atherosclerosis. Nevertheless, the 
most significant findings of the present study were derived from the comparisons between stable and unstable 
advanced lesions, which are not confounded by the same factor. A considerable limitation is, however, that most 
of the findings are based on mRNA level analyses and it remains to be determined whether the observed changes 
are also present at the protein level in human atherosclerotic plaques.
In conclusion, the present study demonstrates that the expression of POMC and the enzymes involved in the 
processing of its cleavage product, α-MSH, associate with plaque stability. The results also further consolidate the 
role of POMC-derived α-MSH in regulating reverse cholesterol transport and reveal a possible disturbance in this 
regulatory pathway after manifestation of CAD. Hence, pharmacological means to increase α-MSH bioavailabil-
ity, e.g. via inhibition of PRCP, could provide a therapeutic strategy to treat atherosclerotic cardiovascular disease, 
but future mechanistic experiments will be instrumental to clarify the role of PRCP in atherosclerosis.
Materials and Methods
Tampere vascular study (TVS) samples. Endarterectomy samples were obtained from femoral and 
carotid arteries, and abdominal aortas of patients fulfilling the following inclusion criteria: (1) carotid endarter-
ectomy because of asymptomatic or symptomatic and hemodynamically significant (>70%) carotid stenosis or 
(2) femoral or (3) aortic endarterectomy with aortoiliac or aortobifemoral bypass because of symptomatic periph-
eral arterial disease18,42. The left internal thoracic artery (LITA) samples, obtained during coronary artery bypass 
surgery, served as controls. Gene expression was analyzed from carotid (n = 29), abdominal aortic (n = 15), and 
femoral (n = 24) plaques and histologically atherosclerosis-free LITAs (n = 24). The type V and VI atherosclerotic 
lesions, according to the American Heart Association recommendation43, were further histologically classified 
as stable or unstable according to the presence of fissure, rupture, hemorrhage and thrombosis. The study was 
approved by the Ethics Committee of Tampere Hospital District and conducted according to the declaration of 
Helsinki, and the study subjects gave informed consent.
Whole blood and monocyte samples. TVS whole blood and monocyte fractions were collected 
and used for genome-wide analysis of gene expression during 2008. The samples were selected from a larger 
population-based cross-sectional study comprising patients subjected to an exercise test at Tampere University 
Hospital and thereafter treated according to the Finnish Current Care Guidelines44. RNA was isolated from the 
whole blood and monocyte fractions of individuals with angiographically verified coronary artery disease (CAD) 
(n = 55) and without coronary artery lesions (non-CAD) (n = 45). Monocytes were isolated from the whole 
blood samples by Ficoll-Paque density-gradient centrifugation (Amersham Pharmacia Biotech UK Limited, 
Buckinghamshire, England).
Mouse atherosclerosis samples. Mouse atherosclerosis samples were derived from 6-month-old female 
apolipoprotein E deficient (Apoe−/−) mice. Mice were fed ad libitum a regular chow diet or a cholesterol-rich diet 
(RD Western Diet, D12079B, Research Diets Inc, NJ, USA) for 12 weeks to promote atherosclerosis. At the end of 
the experiment, mice were euthanized via CO2 asphyxiation and aortic roots were harvested and fixed overnight 
in formalin. The animal experiment was approved by the local ethics committee (Animal Experiment Board in 
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Finland, License Number: ESAVI/6280/04.10.07/2016) and conducted in accordance with the institutional and 
national guidelines for the care and use of laboratory animals.
RNA isolation and genome-wide expression analysis. The fresh arterial tissue samples were soaked 
in RNALater solution (Ambion Inc., Austin, TX, USA) and isolated with Trizol reagent (Invitrogen, Carlsbad, 
CA, USA) and the RNAEasy Kit (Qiagen, Valencia, CA, USA). RNA from whole blood fractions was extracted 
with PAXgene tubes (BD, Franklin Lakes, NJ) and PAXgene Blood RNA Kit (Qiagen) with DNase Set. Peripheral 
mononuclear cells were isolated from the whole blood samples by Ficoll-Paque density-gradient centrifugation 
(Amersham Pharmacia Biotech UK Limited, Buckinghamshire, England) and total RNA was then extracted 
using RNeasy Mini Kit (Qiagen). Thereafter, 200 ng aliquots of total RNA from each sample were converted to 
cDNA (Illumina RNA Amplification kit, iAmbion, Inc., Austin, TX, USA). The expression levels of arterial and 
whole blood samples were analyzed with Illumina HumanHT-12 v3 Expression BeadChip (Illumina, San Diego, 
CA). Monocyte samples were analyzed using Sentrix Human-6 Expression BeadChips (Illumina). After back-
ground subtraction, raw expression data were imported into R version 3.1.1 (http://www.r-project.org/), log2 
transformed and normalized by the locally estimated scatterplot smoothing normalization method implemented 
in the R/Bioconductor package Lumi (www.bioconductor.org). The accuracy of this method has been previously 
tested in our TVS validation study, showing good correlation between expression measurements by microarray 
and RT-PCR methods (r = 0.87, y = 0.151 + 0.586×)16.
Immunohistochemistry and immunofluorescence. Formalin-fixed and paraffin-embedded human 
endarterectomy and mouse aortic root sections were immunostained using a rabbit polyclonal antibody against 
α-MSH (dilution 1:2000, Immunostar, Inc., Hudson, WI, USA, Cat No: 20074)9 or a rabbit polyclonal antibody 
against PRCP (dilution 1:250, Sigma-Aldrich, St. Louis, MO, Cat No: HPA017065). Briefly, sections were dep-
araffinized, rehydrated, and exposed to antigen-retrieval protocol with 10 mM sodium citrate buffer (pH 6). 
Sections were thereafter quenched for endogenous peroxidase activity using 1% H2O2 in Tris-buffered saline 
(TBS), blocked with 10% normal horse serum and incubated with the primary antibody (dilution 1:2000) over-
night at 4 °C. Control sections were incubated with a rabbit IgG isotype control antibody (Novus Biologicals, 
Littleton, CO, USA, Cat No: NBP2-24891) (Supplementary Fig. VIII and IX). Primary antibody binding was 
detected with a horseradish peroxidase-conjugated secondary antibody and diaminobenzidine (ABC kit, Vector 
Labs, Burlingame, USA). For double immunofluorescence, sections were incubated additionally with a rat Mac-2 
antibody (Cedarlane Labs, Burlington, ON, Canada) and then with fluorochrome-conjugated secondary anti-
bodies (anti-rabbit Alexa Fluor 647 and anti-rat Alexa Fluor 488, Jackson ImmunoResearch, West Grove, USA). 
Sections were counterstained with hemotoxylin (CarlRoth, Karsruhe, Germany) or DAPI (Fluoroshield mount-
ing medium, Abcam, Cambridge, UK), coverslipped and then scanned with a digital slide scanner (Pannoramic 
250 or Pannoramic Midi with Zeiss filter sets for FITC, Cy5 and DAPI, 3DHISTECH Kft., Budapest, Hungary).
Quantitative RT-PCR. Total RNA from the aorta of Apoe−/− mice was extracted (Qiagen, Venlo, 
Netherlands) and reverse-transcribed (Takara Clontech). Quantitative RT-PCR was performed using SYBR 
Green protocols (Kapa Biosystems, MA, USA) on an Applied Biosystems 7300 Real-Time PCR system. Samples 
were run in duplicate. Target gene mRNA expression levels were normalized to the geometric mean of riboso-
mal protein S29 and β-actin using the comparative ΔCt method and are presented as relative transcript levels 
(2−ΔΔCt). Primer sequences were as follows: POMC (forward): 5′-caagccggtgggcaagaaacg-3′ and POMC (reverse): 
5′-ctaatggccgctcgccttccag-3′. The primers for S29 and β-actin have been previously reported45.
Statistical analysis. Statistical analyses were performed with GraphPad Prism 6 (GraphPad Software 
Inc., La Jolla, CA, USA). Comparisons of gene expression between controls and cases were performed using 
log-transformed data and Student’s t test, the nonparametric Mann-Whitney U test or one-way ANOVA 
and Bonferroni post hoc test. Pearson or nonparametric Spearman correlation coefficients were calculated 
for gene associations based on D’Agostino-Pearson ominibus normality test results. All data are presented as 
mean ± standard error of the mean (SEM). A two-tailed P value of <0.05 was considered statistically significant.
Data Availability
All data analyzed during this study are included in the published article and its Supplementary Information file or 
can be requested from the corresponding author.
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